@article {10.3844/ajassp.2011.758.761,
article_type = {journal},
title = {Anti-β2 Glycoprotein-I Antibody in Acute Myocardial Infarction},
author = {Shojaei, Mohammad and Jahromi, Abdolreza Sotoodeh and Ebadat, Hamideh and Moosavy, Seyed Hamid and Seddigh, Bita and Madani, Abdolhossien},
volume = {8},
year = {2011},
month = {Jul},
pages = {758-761},
doi = {10.3844/ajassp.2011.758.761},
url = {https://thescipub.com/abstract/ajassp.2011.758.761},
abstract = {Problem statement: Ischemic cardiac manifestations have been reported in a various percentage of patients with anti-phospholipid antibodies. Data concerning the relation between anti- Phospholipid (aPL) antibodies and myocardial infarction in subjects without evidence of overt autoimmune disease are conflicting. Anti-beta2 glycoprotein-I (anti-beta2-GPI) antibody is detected in various diseases like rheumatoid arthritis, systemic lupus erythematosus and anti-phospholipid antibody syndrome. The study of anti-beta2-GPI antibody in Acute Myocardial Infarction (AMI) might shed light on etiologic mechanisms in the pathogenesis of acute coronary syndromes. The purpose of the present study was to determine association of plasma aPL antibodies, namely, antibeta2- GPI antibodies, with AMI. This study was designed to investigate whether prevalence of antibeta2- GPI antibodies, in patients who had acute myocardial infarction and to analyze their relationship with traditional cardiovascular risk factors. Approach: We investigated the prevalence of anti-beta2- GPI IgG in a well characterized group of patients with AMI as a case group. Sera from 74 patients with AMI and from 76 healthy subjects, matched for age and sex as a control group. Using ELISA to evaluate the presence of IgG isotype of anti-beta2-GPI autoantibodies in their sera. Results: The prevalence of anti-beta2-GPI IgG in the control group (10.50%) resulted significantly lower than in patients with AMI (37.80%) (p},
journal = {American Journal of Applied Sciences},
publisher = {Science Publications}
}